Spots Global Cancer Trial Database for bez235
Every month we try and update this database with for bez235 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy | NCT01856101 | Carcinoma Trans... | BEZ235 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | NCT01495247 | Inoperable Loca... Metastatic Brea... | BEZ235 Paclitaxel | 18 Years - | Novartis | |
| BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) | NCT01453595 | Renal Cancer | BEZ235 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | NCT01288092 | Metastatic Brea... | BEZ235 | 18 Years - | Novartis | |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | NCT00620594 | Breast Cancer Advanced Solid ... Cowden Syndrome | BEZ235 | 18 Years - | Novartis | |
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | NCT01634061 | Castration-resi... | BEZ235 BKM120 BEZ235 BKM120 | 18 Years - | Novartis | |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | NCT01285466 | Metastatic or L... | BEZ235 + paclit... BKM120 + paclit... BEZ235 + paclit... BKM120 + paclit... | 18 Years - | Novartis | |
| A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia | NCT01756118 | Acute Lymphobla... Leukemia, Myelo... Chronic Myeloge... | BEZ235 | 18 Years - | Goethe University | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | NCT01658436 | Pancreatic Neur... | BEZ235 (Stage 1... | 18 Years - | Novartis | |
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | NCT01343498 | Malignant Solid... | BEZ235 | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors | NCT01195376 | Advanced Solid ... | BEZ235 | 20 Years - | Novartis | |
| Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy | NCT01856101 | Carcinoma Trans... | BEZ235 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer | NCT01288092 | Metastatic Brea... | BEZ235 | 18 Years - | Novartis | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | NCT01290406 | Endometrial Can... | BEZ235 | 18 Years - | Novartis | |
| A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer | NCT01717898 | Castrate-resist... | BEZ235 Prednisone Abiraterone ace... | 18 Years - | University of California, San Francisco | |
| BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | NCT01658436 | Pancreatic Neur... | BEZ235 (Stage 1... | 18 Years - | Novartis | |
| BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) | NCT01453595 | Renal Cancer | BEZ235 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | NCT01508104 | Cancer | BEZ235 Everolimus | 18 Years - | University of Cincinnati | |
| BEZ235 Trial in Patients With Advanced Endometrial Carcinoma | NCT01290406 | Endometrial Can... | BEZ235 | 18 Years - | Novartis | |
| PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer | NCT01248494 | Metastatic Brea... | BEZ235 BKM 120 Letrozole BKM120 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | NCT01285466 | Metastatic or L... | BEZ235 + paclit... BKM120 + paclit... BEZ235 + paclit... BKM120 + paclit... | 18 Years - | Novartis | |
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | NCT01634061 | Castration-resi... | BEZ235 BKM120 BEZ235 BKM120 | 18 Years - | Novartis | |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | NCT00620594 | Breast Cancer Advanced Solid ... Cowden Syndrome | BEZ235 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
